Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 11 - 29 save search
MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
Published: 2021-11-29 (Crawled : 22:00) - biospace.com/
MEIP | $3.25 4.4K
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
phase 2 ongoing
BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile
Published: 2021-11-29 (Crawled : 15:00) - biospace.com/
BETRF | $0.074 450
|
Health Technology
|
| O: -2.17%
H: 5.94%
C: -1.2%
phase 2 trials trial covid clinical trials phase 1
Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies
Published: 2021-11-29 (Crawled : 14:30) - biospace.com/
RARE | $43.25 0.89% 110K
|
Health Technology
|
| O: 2.82%
H: 0.06%
C: -6.28%
gene therapy multi-year phase 1 positive therapy phase 2 phase 3
ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study
Published: 2021-11-29 (Crawled : 14:00) - biospace.com/
NDRA | $0.262 37K
|
Health Technology
|
| O: 9.27%
H: 2.83%
C: -6.58%
partnership phase 2 technology life science biomarkers
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC)
Published: 2021-11-29 (Crawled : 13:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.275 -0.81% 130K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
phase 2 trilaciclib antibody drug trial therapeutics
Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A
Published: 2021-11-29 (Crawled : 13:00) - biospace.com/
SGTX | $22.47 -2.56% 0.0% 0
|
Health Technology
|
| O: -7.18%
H: 8.0%
C: 0.53%
phase 1 therapeutics phase 2 phase 3
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
KRON | $1.13 -0.88% 93K
|
Health Technology
|
| O: 1.51%
H: 1.09%
C: -9.6%
ongoing phase 1 positive trial phase 2
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GTHX | $4.275 -0.81% 130K
|
Health Technology
|
| O: 0.75%
H: 0.82%
C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics
SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
SWTX | $42.48 -0.63% 110K
|
Health Technology
|
| O: 0.0%
H: 3.75%
C: -3.69%
phase 2 phase 2b trial therapeutics enroll
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.